Exelixis Initiating Phase 3 Pivotal Trial (COSMIC-313) of Cabozantinib in Combination with Nivolumab and Ipilimumab Versus Nivolumab and Ipilimumab in Previously Untreated Advanced Renal Cell Carcinom
Go back to Exelixis Initiating Phase 3 Pivotal Trial (COSMIC-313) of Cabozantinib in Combination with Nivolumab and Ipilimumab Versus Nivolumab and Ipilimumab in Previously Untreated Advanced Renal Cell Carcinom| Exelixis, Inc. (NASDAQ: EXEL) | Delayed: 51.91 -0.53 (1.01%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $52.44 | 52 Week High | $17.00 | |||
| Open | $53.07 | 52 Week Low | $3.55 | |||
| Day High | $53.12 | P/E | N/A | |||
| Day Low | $50.96 | EPS | $-1.33 | |||
| Volume | 6,545,172 | |||||
